OIPE JC10
AUG 01 2005
PATENT & TRADEMARK OFFICE

IFW CC

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Gleave, et al. Application No.: 10/646,391 Filed: 8/21/2003 Title: Treatment of Melanoma by Reduction in Clusterin Levels Attorney Docket No.: UBC.P-035	Group Art Unit: 1614 Examiner:

Assistant Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Applicants request that the references listed on Substitute for form PTO 1449, which is attached, be made of record in the US Patent and Trademark Office in the file relating to the above-captioned application. Copies of the listed references are enclosed.

Applicants enclose the fee for submission of this IDS. The Commissioner is authorized to charge any fees due in connection with this paper or credit any overpayment to Deposit Account No. 15-0610.

Cert. Under 37 CFR 1.8
This paper and the attachments named herein are being deposited with the United States Postal Service with sufficient postage as first class mail and addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450 on

JUL - 8 2005

Name Sandra Lahmann

Signature Sandra Lahmann

Respectfully Submitted,

Marina T Larson

Marina T. Larson, Ph.D
Attorney/Agent for Applicant(s)
Reg. No. 32038

(970) 468 6600

08/02/2005 CNGUYEN2 00000046 10646391 180.00 OP
01 FC:1806

OIPE JC10
AUG 01 2005
PATENT & TRADEMARK OFFICE

PTO/SB/08a (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	1	of	4

Complete if Known	
Application Number	10/646,391
Filing Date	8/21/2003
First Named Inventor	Gleave et al.
Art Unit	1614
Examiner Name	
Attorney Docket Number	UBC.P-035

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US-5,646,042	07-08-1997	Stinchcomb et al.	
		US-5,789,389	08-04-1998	Tarasewicz et al.	
		US-5,929,040	07-27-1999	Werther et al.	
		US-5,998,148	12-07-1999	Bennet et al.	
		US-6,172,216 B1	01-09-2001	Bennett et al.	
		US-6,335,194 B1	01-01-2002	Bennett et al.	
		US-6,383,808 B1	05-07-2002	Monia et al.	
		US-2003/0158130 A1	08-21-2003	Gleave et al.	
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3] -Number[4]- Kind Code[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
		WO 00/34469	06-15-2000	The Research Foundation of		
		WO 00/49937	08-31-2000	The University of British		
		WO 01/46455 A2	06-28-2001	Yale University		
		WO 02/22635 A1	03-21-2002	ISIS Pharmaceuticals, Inc.		
		WO 03/062421 A1	07-31-2003	The University of British		
		WO 03/072591 A1	09-04-2003	The University of British		
		WO 2004/018675 A1	03-04-2004	The University of British		
		WO 2004/018676 A2	03-04-2004	The University of British		

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of US PTO Patent Documents at www.upsto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

PTO/SB/08b (08-03)
Approved for use through 06/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 2 of 4

Complete if Known	
Application Number	10/646,391
Filing Date	8/21/2003
First Named Inventor	Gleave et al.
Art Unit	1614
Examiner Name	
Attorney Docket Number	UBC.P-035

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
		AGRAWAL ET AL., Antisense Therapeutics: is it as simple as complementary base recognition, Molecular Medicine Today, 2000, Page(s) 72-81, Volume 6, Publisher: Elsevier Science Ltd.	
		AOKI ET AL., RNA Intereference may be more potent than antisense RNA in human cancer cell lines, Clinical and Experimental Pharmacology and Physiology, 2003, Page(s) 96-102	
		BENNER ET AL., Combination of Antisense Oligonucleotide and Low-Dose Chemotherapy in Hematological Malignancies, Journal of Pharmacological and Toxicological Methods, 1997, Page(s) 229-235, Publisher: Elsevier Science Inc.	
		BORAL ET AL., Clinical evaluation of biologically targeted drugs: obstacles and opportunities, Cancer Chemother Pharmacol, 1998, Page(s) S3-S21, Publisher: Springer-Verlag	
		ANDREA D. BRANCH, A good antisense molecule is hard to find, TIBS, 1998, Page(s) 45-50, Publisher: Elsevier Science Ltd.	
		STEVEN BREM, MD, Angiogenesis and Cancer Control: From Concept to Therapeutic Trial, Cancer Control Journal, 1999, Volume 6, Number 5, Publisher: H. Lee Moffitt Cancer Center & Research Institute	
		BRUCHOVSKY ET AL., Control of Tumor Progression by Maintenance of Apoptosis, www.prostatepointers.org, 1996, Publisher: Wiley-Liss, Inc.	
		BUTTYAN ET AL., Induction of the TRPM-2 Gene in Cells Undergoing Programmed Death, Molecular and Cellular Biology, 1989, Page(s) 3473-3481, Volume 9, Number 8, Publisher: American Society for Microbiology	
		COX ET AL., Angiogenesis and non-small cell lung cancer, Lung Cancer, 2000, Page(s) 81-100, Publisher: Elsevier	
		CROOKE ET AL., Basic principles of antisense therapeutics, Antisense Research and Application, 2004, Page(s) 1-50, Chapter 1, Publisher: Springer	
		DARBY ET AL., Vascular Expression of Clusterin in Experimental Cyclosporine Nephrotoxicity, Exp Nephrol, 1995, Page(s) 234-239, Publisher: S. Karger AG	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

PTO/SB/08b (08-03)
Approved for use through 06/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	3	of	4

	Complete if Known
Application Number	10/646,391
Filing Date	8/21/2003
First Named Inventor	Gleave et al.
Art Unit	1614
Examiner Name	
Attorney Docket Number	UBC.P-035

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
		DIEMER ET AL., Expression of Porcine Complement Cytolysis Inhibitor mRNA in Cultured Aortic Smooth Muscle Cells, The Journal of Biological Chemistry, March 15, 1992, Page(s) 5257-5264, Volume 207, Number 8, Publisher: The AMerican Society for Biochemistry and Molecular Biology, Inc.	
		GENTA, New Data Reaffirm Genta's Molecular Target as Critical Factor for Enhancing Anticancer Treatment, www.genta.com, 2001	
		JEN ET AL., Suppression of Gene Expression by Targeted Disruption of Messenger RNA: Available Options and Current Strategies, Stem Cells 2000, 2000, Page(s) 307-319, Volume 18	
		KADOMATSU ET AL., Expression of sulfated glycoprotein 2 is associated with carcinogenesis induced by N-nitroso-N-methylurea in rat prostate..., Cancer Res, April 1, 1993, Page(s) 1480-1483, Volume 53, Number 7	
		KIRBY ET AL, Bartonella-associated endothelial proliferation depends on inhibition of apoptosis, PNAS, April 2, 2002, Page(s) 4656-4661, Volume 99, Number 7	
		KYPRIANOU ET AL., bcl-2 over-expression delays radiation-induced apoptosis without affecting the clonogenic survival of human prostate , International Journal of Cancer, January 27, 1997, Page(s) 341-348, Volume 70, Number 3	
		LEE ET AL., In Vitro Models of Prostate Apoptosis: Clusterin as an Antiapoptotic Mediator, The Prostate Supplement, 2000, Page(s) 21-24, Volume 9, Publisher: Wiley-Liss, Inc.	
		MILLAR ET AL., Localization of mRNAs by in-situ hybridization to the residual body at stages IX-X of the cycle of the rat seminiferous , International Journal of Andrology, 1994, Page(s) 149-160, Volume 17	
		MILLIS ET AL., Clusterin Regulates Vascular Smooth Muscle Cell Nodule Formation and Migration, Journal of Cellular Physiology, 2001, Page(s) 210-219, Volume 186, Publisher: Wiley-Liss, Inc.	
		MILNER ET AL., Selecting effective antisense reagents on combinatorial oligonucleotide arrays, Nature Biotechnology, 1997, Page(s) 537-541, Volume 15	
		NÖR ET AL., Engineering and Characterization of Functional Human Microvessels in Immunodeficient Mice, Laboratory Investigation, 2001, Page(s) 453-463, Volume 81, Number 4	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

PTO/SB/08b (08-03)
Approved for use through 06/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	4	of	4

Complete if Known	
Application Number	10/646,391
Filing Date	8/21/2003
First Named Inventor	Gleave et al.
Art Unit	1614
Examiner Name	
Attorney Docket Number	UBC.P-035

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
		NÖR ET AL., Up-Regulation of Bcl-2 in Microvascular Endothelial Cells Enhances Intratumoral Angiogenesis and Accelerates Tumor Growth, March 1, 2001, Page(s) 2183-2188, Volume 61	
		OPALINSKA ET AL., Nucleic-acid therapeutics: Basic principles and recent applications, Nature Reviews, 2002, Page(s) 503-514, Volume 1	
		TRAN ET AL., A role for survivin in chemoresistance of endothelial cells mediated by VEGF, PNAS, April 2, 2002, Page(s) 4349-4354, Volume 99, Number 7	
		TROUGAKOS ET AL., Silencing Expression of the Clusterin/Apolipoprotein J Gene in Human Cancer Cells Using Small Interfering RNA Induces , Cancer Research, March 1, 2004, Page(s) 1834-1842, Volume 64	
		VICKERS ET AL., Efficient Reduction of Target RNAs by Small Interfering RNA and RNase H-dependent Antisense Agents, The Journal of Biological Chemistry, February 28, 2003, Page(s) 7103-7118, Volume 278, Number 9	
		WRIGHT ET AL., A ribonucleotide reductase inhibitor, MDL 101,731, induces apoptosis and elevates TRPM-2 mRNA levels in human prostate , Experimental Cell Research, January 10, 1996, Page(s) 54-60, Volume 222, Number 1	
		YANG ET AL., Nuclear clusterin/XIP8, an x-ray-induced Ku70-binding protein that signals cell death, PNAS, May 23, 2000, Page(s) 5907-5912, Volume 97, Number 11	
		ZWAIN ET AL., Clusterin Protects Granulosa Cells from Apoptotic Cell Death during Follicular Atresia, Experimental Cell Research, 2000, Page(s) 101-110, Volume 257, Publisher: Academic Press	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98: The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.